Mundipharma to launch biosimilar monoclonal antibody for the treatment of cancer

Pharmaceutical and biotech partnering company Mundipharma, is set to launch Truxima, the first biosimilar monoclonal antibody authorised by the European Comission (EC) for the treatment of cancers.

The company will launch the drug in the UK, Italy, Netherlands, Belgium, Republic of Ireland and Luxembourg, following authorisation by the European Medicines Agency (EMA).

Truxima is authorised for the treatment of diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

One of the world’s top selling cancer drug, Mabthera, is what Truxima is referenced off. Mundipharma hopes that Truxima will cost less than the reference product and enable access for patients in need of new innovative cancer therapies.

In 2015 Mundipharma launched infliximab, the first biosimilar monoclonal antibody. Truxima is the second biosimilar monoclonal antibody to be marketed and distributed by Mundipharma.

Antony Mattessich, managing director, Mundipharma said: “Mundipharma is constantly seeking opportunities to develop and commercialise sustainable, responsible medicines for a complex and cost conscious world. With our global reach, European expertise and proven track record, we are an attractive partner for any companies looking to commercialise biosimilars in Europe and are looking forward to further expand our portfolio in this complex and rapidly growing area.”